The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril
Objective To compare the antihypertensive efficacy and systemic tolerability of valsartan , a new angiotensin II receptor antagonist , with placebo and with an angiotensin converting enzyme ( ACE ) inhibitor , enalapril . Design A total of 348 adult out patients with mild-to-moderate uncomplicated essential hypertension participated in this double-blind , parallel , study . Patients were allocated r and omly in a ratio of 2:2:1 to receive 80 mg valsartan once a day , 20 mg enalapril once a day , or placebo for 8 weeks in general practice . Patients were assessed at 4 and 8 weeks of therapy . Main outcome measures The primary efficacy variable was the change from baseline in mean sitting diastolic blood pressure ( SDBP ) after 8 weeks of therapy . Secondary variables included the change in sitting systolic blood pressure ( SSBP ) and response rates at 8 weeks . Results Valsartan and enalapril produced statistically significant reductions in diastolic and systolic blood pressures compared with placebo . Similar falls were found in both of the active treatment groups with mean changes in SDBP at 8 weeks of — 9.5mmHg for valsartan and — 9.4mmHg for enalapril ( 4.5mmHg for placebo ) . No significant differences between valsartan and enalapril were found for reductions in SDBP or SSBP . Response rates at 8 weeks were significantly greater for valsartan ( 54 % ) and enalapril ( 58 % ) than for placebo ( 20 % ) , with no significant difference between the two active treatments . Both valsartan and enalapril demonstrated a consistent a nti hypertensive effect over time , with 90 % of patients with a response at 4 weeks responding at 8 weeks . Both of the treatments were tolerated well . Although the incidence of coughing was generally low in the study , more cases were reported with enalapril ( three ) than with valsartan ( one ) or placebo ( none ) . Conclusions The data show 80 mg valsartan once a day to be as effective as 20 mg enalapril once a day in the treatment of mild-to-moderate hypertension . Valsartan is tolerated well and does not appear to be associated with any increase in the incidence of coughing
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .